Sialix, a Cambridge, Mass.-based developer of products that treat cancer and chronic inflammatory conditions, raised $1m in financing.
Backers included Boston Harbor Angels, Mass Medic Angels, Launchpad Angels and Maine Angels, as well as other undisclosed individuals. In conjunction with the funding, Brad Curley, a member of Boston Harbor Angels, joined the company’s board of directors; Richard Anders, founder of Mass Medic Angels, will act as a board observer; and, Dr. Peter Kiener, will serve as a business and scientific advisor.
Led by Jeff Behrens, president and CEO, Sialix is developing products for the treatment and prevention of cancer and chronic inflammatory conditions associated with ingestion of non-human sialic acids which are found in red meat and other dietary sources.
The company is advancing two complementary programs:
– an oncology therapeutic targeting ovarian and other solid tumors, and
– a prophylactic nutritional supplement to reduce inflammation and the resulting risk of cancer and cardiovascular disease.